Varying responses to arsenic reinduction treatment observed in patients with relapsed APL and carrying genetic mutations within PML-RARA
| Patient No. . | Acquired mutations . | APL cells in bone marrow . | |
|---|---|---|---|
| Before reinduction treatment . | After reinduction treatment . | ||
| 1 | A216V | 48% | 20% |
| 2 | A216V | 2%*a | 43% |
| 3 | A216V | 10% | UA |
| 4 | S214L+A216T | 48% | 52% |
| 5 | A216T | 2%*b | 15% |
| 6 | A216T | 66% | 46% |
| 7 | A216T | 44% | 85% |
| 8 | L217F | 96% | 0 |
| 9 | S220G | 69% | 11% |
| Patient No. . | Acquired mutations . | APL cells in bone marrow . | |
|---|---|---|---|
| Before reinduction treatment . | After reinduction treatment . | ||
| 1 | A216V | 48% | 20% |
| 2 | A216V | 2%*a | 43% |
| 3 | A216V | 10% | UA |
| 4 | S214L+A216T | 48% | 52% |
| 5 | A216T | 2%*b | 15% |
| 6 | A216T | 66% | 46% |
| 7 | A216T | 44% | 85% |
| 8 | L217F | 96% | 0 |
| 9 | S220G | 69% | 11% |
UA, unavailable (as described in the text).
The percentage of APL cells in bone marrow from included patients were examined before and after reinduction treatment with arsenic.
Relapse occurred at the molecular level. The expression levels of PML-RARA transcripts are represented by “a” (39.8%) and “b” (14.3%) respectively.